Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Recently, there has been increased concern about a risk of secondary malignancies (SM) occurring in myelofibrosis (MF) patients receiving ruxolitinib (RUX). In polycythemia vera (PV), on the other hand, only limited data on the risk of SM under RUX treatment are available. To investigate the association between RUX therapy in PV and SM, we conducte...
Alternative Titles
Full title
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8510903
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8510903
Other Identifiers
ISSN
0939-5555
E-ISSN
1432-0584
DOI
10.1007/s00277-021-04647-0
